Milnubes / Curiosity, with sourcesBotany · Culture · Science
Cannabinoid atlas / Reference entry
CBCA
Plant cannabinoids

Cannabichromenic acid

CBCA has a documented chemical identity and laboratory signals worth following. Antibacterial research is striking, but does not show that a CBCA product treats infections. A culture plate and a patient present different problems.

Detail of veins in a purple leaf with green edges.
Stock botanical detail of a leaf not identified as cannabis. It shows neither CBCA nor a cannabinoid analysis.
Evidence map

Laboratory or animals. This label summarises the type of data; it is neither a recommendation to use nor a safety rating.

How we read studies and personal accounts ↗

Identity

Cannabichromenic acid belongs to the acidic branch of CBC. A 1997 enzymology study documented its formation from CBGA through an enzyme identified in Cannabis.

Terms associated with this entry: cannabichromenic acid, ácido cannabicroménico.

Bacteria in the laboratory

The 2020 study found bactericidal activity against gram-positive bacteria, including MRSA, in laboratory assays. It was not a therapeutic trial in people. Comparison with an antibiotic within the experiment does not justify replacing treatment or claiming clinical superiority.

A second, still preclinical line

In 2021, CBCA showed activity against hyperthermia-induced seizures in mice. This was not a human trial and does not make CBCA identical to CBC.

What has been studied

Laboratory or animals

In-vitro antibacterial activity; experimental interest, not demonstrated clinical benefit.

Risks and gaps

Maintaining viability in some laboratory cells does not establish whole-body or long-term safety.

Documented forms

Experimental laboratory materialThe identified literature describes test compounds, not a recommended clinical preparation.

A molecule and a product are different things. Read about flowers, resins, oils, creams, capsules and vaping.

Experiences

We have not included a verifiable individual account in this review. We do not fill that gap with commercial stories or invented experiences.

Conclusion

CBCA’s profile should remain brief while evidence is limited. Its value lies in identifying real questions without filling space with assumed uses.

Legal context

Read the Spain note and official sources. Absence from a cited list does not establish that a product is lawful.

Sources

  1. Enzymological Evidence for Cannabichromenic Acid Biosynthesis, 1997 · Original research
  2. Rapid Antibacterial Activity of Cannabichromenic Acid against Methicillin-Resistant Staphylococcus aureus, 2020 · Laboratory study
  3. Cannabichromene and related phytocannabinoids in a mouse model of Dravet syndrome, 2021 · Animal study

Source review: 2026-11-02. No external clinical review. Corrections: info@milnubes.com.